share_log

Alpha Tau Medical Announces First Alpha DaRT Patients Treated In France As Part Of Alpha DaRT Multicenter Skin Cancer Trial

Alpha Tau Medical Announces First Alpha DaRT Patients Treated In France As Part Of Alpha DaRT Multicenter Skin Cancer Trial

作爲 Alpha darT 多中心皮膚癌試驗的一部分,Alpha Tau Medical 宣佈首批在法國接受治療 Alpha darT 患者
Benzinga Real-time News ·  2022/05/23 09:08

JERUSALEM, May 23, 2022 /PRNewswire/ -- Alpha Tau Medical (NASDAQ:DRTS) (NASDAQ:DRTSW), the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT™, announced today that the first patients in its French multicenter trial for skin cancer were treated with Alpha DaRT, at the Leon Berard Center in Lyon, France by Dr. Pascal Pommier and his team. The Leon Berard Center specializes in radiotherapy for cancer and is affiliated with the National Federation of Cancer Centers in France - UNICANCER Group. Dr. Pommier is the Principal Investigator of the French multicenter study and has more than 20 years of experience in radiation oncology and leading clinical trials.

耶路撒冷,2022年5月23日 /PRNewswire/ — 開創性的α-放射癌療法Alpha dart™ 的開發者Alpha Tau Medical(納斯達克股票代碼:DRTS)(納斯達克股票代碼:DRTS)今天宣佈,帕斯卡爾·波米爾博士及其團隊在法國里昂的萊昂·貝拉德中心接受了Alpha dart治療的法國皮膚癌多中心試驗中的第一批患者。萊昂·貝拉德中心專門研究癌症放射治療,隸屬於法國全國癌症中心聯合會——UNICANCER集團。Pommier博士是法國多中心研究的首席研究員,在放射腫瘤學和領先的臨床試驗方面擁有超過20年的經驗。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論